Drug
Idalopirdine
Idalopirdine: highest development phase Phase 3, developed by Lundbeck. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Lundbeck
Trials
| Drug | Phase | Indication |
|---|---|---|
| Idalopirdine NCT02006641 | Phase 3 | Alzheimer's Disease |
| Idalopirdine (Lu AE58054) 60 mg NCT02340195 | Phase 1 | Alzheimer Disease |
Latest
No recent events.
Follow Idalopirdine on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.